Author:
Yagi H,Miyamoto S,Tanaka Y,Sonoda K,Kobayashi H,Kishikawa T,Iwamoto R,Mekada E,Nakano H
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Aberbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292–4302
2. D'Antonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A, Tambaro R, Bianco C, Gullick WJ, Johnson GR, Iaffaioli VR, Salomon DS, Normanno N (2002) Transforming growth factor alpha, AR and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int J Oncol 21: 941–948
3. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB (2000) Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 6: 2482–2491
4. Fischer OM, Hart S, Gschwind A, Ullrich A (2003) EGFR signal transactivation in cancer cells. Biochem Soc Trans 31: 1203–1208
5. Goetzl EJ, Kong Y, Kenney JS (1999) Lysophospholipid enhancement of human T cell sensitivity to diphtheria toxin by increased expression of heparin-binding epidermal growth factor. Proc Assoc Am Physicians 111: 259–269
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献